RxDoctor Payments Data

Jocelyn Zarate, MD

Internal Medicine · San Antonio, TXNPI 1427054055

Payments from drug & device makers

$1,679in general payments, 2019–2025

Across 87 payments — averaging $19.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$322
  • Lilly USA, LLC$236
  • Teva Pharmaceuticals USA, Inc.$180
  • GSK$111
  • Merck$105
  • Novo Nordisk$90
  • plus $634 from 19 others

What the payments were for

  • Food & beverage$1,679100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,679 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$65,261
Medicare patients
130
Services billed
863

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$71,654
EliquisApixaban129$58,267
JardianceEmpagliflozin57$42,641
MounjaroTirzepatide22$34,428
MyrbetriqMirabegron89$32,838
JanuviaSitagliptin Phosphate13$21,089
XareltoRivaroxaban35$19,889
NuedextaDextromethorphan Hbr/Quinidine11$17,406
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$11,631
NamzaricMemantine Hcl/Donepezil Hcl22$6,145
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen142$5,367
RestasisCyclosporine12$4,424
Eszopiclone13$3,276
Gabapentin186$3,275
Levothyroxine Sodium266$3,229

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$90$71,65465 claims
PfizerEliquis$84$58,267129 claims
Boehringer IngelheimJardiance$22$42,64157 claims
Lilly USA, LLCMounjaro$236$34,42822 claims
MerckJanuvia$105$21,08913 claims
Johnson & JohnsonXarelto$36$19,88935 claims
AbbVieNamzaric, Restasis, Synthroid$61$13,71468 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →